Shumin Ouyang

State Key Laboratory Of Anti Infective Drug Discovery And Development, Guangdong Key Laboratory Of Chiral Molecule And Drug Discovery
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.

Targeting STAT3-mediated lipid metabolism reprogramming overcomes chemoresistance in acute myeloid leukemia.

Journal: Cell death & disease

Published: November 29, 2025

Simultaneous Repair of Iatrogenic Left Atrial and Aortic Perforations Using Ductus Arteriosus Occluders: A Case Report.

Simultaneous Repair of Iatrogenic Left Atrial and Aortic Perforations Using Ductus Arteriosus Occluders: A Case Report.

Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Published: September 22, 2025

A Case of Venous Tissue Dissection During Transcatheter MitraClip Surgery.

A Case of Venous Tissue Dissection During Transcatheter MitraClip Surgery.

Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Published: June 09, 2025

The IGF2BP3-FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer.

The IGF2BP3-FASN axis drives lipid metabolic reprogramming to promote brain colonization in non-small cell lung cancer.

Journal: Cell death & disease

Published: February 08, 2025

Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer.

Neuropeptide Precursor VGF Promotes Neuroendocrine Differentiation and Cancer-Associated Fibroblast Activation in Small Cell Lung Cancer.

Journal: Cancer research

Published: January 27, 2025

A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions.

A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions.

Journal: European journal of pharmacology

Published: November 02, 2024

Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer.

Periostin-mediated NOTCH1 activation between tumor cells and HSCs crosstalk promotes liver metastasis of small cell lung cancer.

Journal: Journal of experimental & clinical cancer research : CR

Published: September 05, 2024

Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops.

Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: July 13, 2024

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.

Reprogramming of TAMs via the STAT3/CD47-SIRPα axis promotes acquired resistance to EGFR-TKIs in lung cancer.

Journal: Cancer letters

Published: January 16, 2023

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia.

Targeting STAT3-VISTA axis to suppress tumor aggression and burden in acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: December 16, 2022

Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3.

Boronic Acid: A Novel Pharmacophore Targeting Src Homology 2 (SH2) Domain of STAT3.

Journal: Journal of medicinal chemistry

Published: September 28, 2022

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.

Journal: Cancer research

Published: September 27, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026